{
  "name": "Thymosin Alpha-1",
  "category": "peptide",
  "evidenceGrade": "B",
  "riskProfile": "medium",
  "description": "A thymic peptide that modulates the immune system by stimulating T-cell maturation and function. FDA-approved as orphan drug (Zadaxin) for hepatitis B. Used clinically in over 30 countries for immunomodulation and shows promise for immune aging.",
  "mechanisms": [
    "T-cell maturation and differentiation",
    "Dendritic cell activation",
    "NK cell enhancement",
    "Toll-like receptor signaling modulation"
  ],
  "dosage": {
    "standard": "1.6mg subcutaneous, 2x/week",
    "range": "0.8-3.2mg, 2-3x/week",
    "notes": "Subcutaneous injection. FDA orphan drug approval. Used clinically in 30+ countries."
  },
  "keyFindings": [
    "Improved survival in sepsis and hepatitis B in multiple clinical trials",
    "Enhanced vaccine response in immunocompromised elderly patients",
    "Restored T-cell function in aging immune systems (immunosenescence)"
  ],
  "interactions": [
    "Immunosuppressants (may counteract)",
    "Other immunomodulators"
  ],
  "sideEffects": [
    "Injection site reactions",
    "Mild flu-like symptoms (rare)"
  ],
  "contraindications": [
    "Organ transplant recipients on immunosuppressants",
    "Active autoimmune disease"
  ],
  "tags": [
    "peptide",
    "immune",
    "thymus",
    "immunosenescence",
    "clinical",
    "approved"
  ],
  "estimatedMonthlyCost": {
    "low": 100,
    "mid": 250,
    "high": 500,
    "currency": "USD"
  },
  "id": "prod-thymosin-alpha-1",
  "sources": [],
  "suppliers": [],
  "communityReports": [],
  "expertOpinions": [],
  "lastUpdated": "2026-02-04T14:50:14.783Z",
  "createdAt": "2026-02-04T14:50:14.783Z"
}